To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
Alphagan: two drops a day for 28 days
North Bay Eye Associates, Inc.
Petaluma, California, United States
Trough and peak intraocular pressure
Time frame: 2-4 months
Tolerability of study medication
Time frame: 2-4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.